Testing a new antibody drug called GNC-039 in people with glioma or other solid tumors
Original title: A Study of GNC-039, a Tetra-specific Antibody, in Participants With Relapsed/Refractory or Metastatic Solid Tumors
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early safety test in people, so a lot is still unknown.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This trial is testing how safe a new drug called GNC-039 is in people whose tumor has come back or spread.
Who this trial is for. This trial is for people with glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are graded 1 to 4 by how fast they tend to grow. See the glossary or another solid tumor that came back, did not respond to treatment, or has spread. It is testing a drug called GNC-039, which is a tetra-specific antibody.
Where it stands. The trial is looking at how safe the drug is, how well people handle it, and what dose people can take. It is also taking an early look at whether the drug helps. No results have been reported.
What this means, and what it doesn't
What it could mean: This is an early look at a new drug. Someone whose tumor came back or spread could ask their care team if this trial is worth looking into.
What it doesn't mean: This does not mean GNC-039 works. A trial is a test, not a proven treatment. Joining a trial is not a promise that it will help you. It is not a cure.
Source: ClinicalTrials.gov, August 27, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.